The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
Part of paid clinical trials in Fayetteville, Arkansas.
- Sponsor
- University of Arkansas, Fayetteville
- Study ID
- NCT06115603
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Cannabigerol — DRUG1 mL of 80mg Cannabigerol once during experimental session
- Placebo — OTHER1 mL of placebo once during experimental session
Study Details
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
Key Dates
- Start date
- Dec 14, 2024
- Status verified
- May 2026
- Primary completion
- Jul 31, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 76 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Cannabigerol1mL of 80mg of Cannabigerol. Cannabigerol is a safe, legal, non-high-inducing cannabinoid obtained from the cannabis plant.
- Placebo Comparator: Placebo1mL of Placebo. Placebo is made in the form of MCT oil.
Primary Outcome Measure
Sustained Attention to Response Task [ Time Frame: 75 minutes post CBG/placebo administration ]
Central Contacts
- Ellen W Leen-Feldner, PhD4795754256
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Arkansas | Fayetteville | Arkansas | 72703 | Ellen Leen-Feldner, PhD |
Find similar trials in Fayetteville, AR
By condition
By specialty
By research site
Related Studies
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHDPHASE4 · Recruiting · Supernus Pharmaceuticals, Inc. · Saraland, Alabama
- An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early EveningPHASE4 · Recruiting · NYU Langone Health · New York, New York
- A Pilot Study of a Remote ADHD Monitoring ProgramRecruiting · IDeA States Pediatric Clinical Trials Network · Jackson, Mississippi